Obovatol inhibits NLRP3, AIM2, and non-canonical inflammasome activation
- Obovatol inhibits NLRP3, AIM2, and non-canonical inflammasome activation
- 김진철; 김정은; 안희정; 한병철; 신현정; 정의만; 김주열; 양희정; 이정현; 강승구; 이승호; 이근식
- Issue Date
- Phytomedicine : international journal of phytotherapy and phytopharmacology
- VOL 63-153019-9
Obovatol, a biphenolic chemical originating from Magnolia obovata, has been utilized as a traditional medicine for the treatment of inflammatory diseases. Inflammasome induces maturation of inflammatory cytokines in response to intracellular danger signals, and its dysregulation induces inflammatory diseases.
The effect of obovatol on inflammasome activation has not been reported, although its anti-inflammatory properties have been studied.
Obovatol was treated to macrophages with inflammasome triggers, and secretions of interleukin (IL)-1β, IL-18, and caspase-1 were measured as readouts of inflammasome activation. In addition, Asc pyroptosome formation, caspase-1 activity, and mitochondrial reactive oxygen species (ROS) production were analyzed in mechanical studies. Anti-inflammasome properties of obovatol were confirmed in an animal model.
Obovatol inhibited NLRP3, AIM2, and non-canonical inflammasomes through inhibition of Asc pyroptosome formation and mitochondrial ROS generation. In addition, obovatol disrupted the priming step of inflammasome activation and inhibited transcription of inflammatory cytokines. In mice, obovatol attenuated serum IL-1β elevation in response to monosodium urate crystals.
Obovatol is suggested as an inhibitor of NLRP3, AIM2, and non-canonical inflammasomes.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.